A.Т. Aubakirova ^1,2, G.B. Аbdilova ¹, A.N. Nurgalyeva ¹, G.K. Abdigakyeva ¹, Ye. Serikuly ¹, A.D. Baichalova ¹

1. «National Scientific Center of Surgery named after A.N. Syzganov» JSC, Almaty, the Republic of Kazakhstan;
2. «Kazakh Institute of Oncology and Radiology» JSC, Almaty, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2521-6414-2022-4-66-59-63

UDC: 616-006.6(36):577.21

Year: 2022 issure: 66 number: 4 pages: 59-63

Download PDF:

ABSTRACT

Relevance: Hepatocellular carcinoma (HCC) ranks sixth among the most common malignant neoplasms in the world and accounts for about 5.6% of all human malignant neoplasms. Despite encouraging progress in the diagnosis and treatment of HCC, the prognosis remains unsatisfactory, i.e., with a 5-year overall survival rate below 10.3%. However, the survival rate can reach 50-74% if early detection and therapeutic intervention are carried out on time. However, unfortunately, about 50% of HCC cases are diagnosed at a late stage.
The protein induced by the absence of vitamin K or antagonist-II (PIVKA-II), also known as Dez-γ-carboxyprothrombin (DCP), is another marker specific to HCC. In several studies, elevated PIVKA-II serum levels were associated with HCC. Many authors have proven the PIVKA-II applicability for HCC monitoring.
This study aimed to compare the efficiency of alpha-fetoprotein and des-gamma-carboxyprothrombin serological markers in HCC.
Methods: The study included the review of published articles on the causes of HCC and the analysis of literature to compare cancer markers efficacy, including PIVKA-II and alpha-fetoprotein (AFP), in detecting HCC.
Results: The published results evidence an important role of PIVKA-II in HCC early detection, since PIVKA-II elevation in risk-group patients predicts HCC development in two years. Higher PIVKA-II levels can indicate a bigger tumor or a higher clinical stage. Besides, HCC patients with metastasis to the lymph nodes and distant metastasis had much higher PIVKA-II levels compared to non-metastatic patients. So, high PIVKA-II levels can to a certain extent reflect poor prognosis in HCC patients.
Conclusion: The reviewed publications report much higher PIVKA-II serum levels in patients with HCC compared to patients with benign liver diseases or healthy people. Besides, PIVKA-II has a higher diagnostic capacity than AFP due to its higher levels, sensitivity, and specificity. Thus, we can expect high sensitivity and efficiency of the PIVKA-II oncomarker in HCC early diagnostics.
Keywords: Hepatocellular carcinoma, protein, liver, biomarker, serum.

List of sources used:

1. Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: Evidence from GLOBOCAN 2018 // Jpn. J. Clin. Oncol. – 2020. – Vol. 50(12). – P. 1370-1379. https://doi.org/10.1093/jjco/hyaa130.
2. Arnold M., Abnet C.C., Neale R.E., Vignat J., Giovannucci E.L., McGlynn K.A., Bray F. Global Burden of 5 Major Types of Gastrointestinal Cancer // Gastroenterology. – 2020. – Vol. 159(1). – P. 335-349. https://doi.org/10.1053/j.gastro.2020.02.068.
3. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J. Clin. – 2018. – Vol. 68(9). – P. 394-424. https://doi.org/10.3322/caac.21492.
4. Kudo M., Matsui O., Izumi N., Iijima H., Kadoya M., Imai Y., Okusaka T., Miyayama S., Tsuchiya K., Ueshima K., Hiraoka A., Ikeda M., Ogasawara S., Yamashita T., Minami T., Yamakado K., Liver Cancer Study Group of Japan. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan // Liver Cancer. – 2014. – Vol. 3(3-4). – P. 458-468. https://doi.org/10.1159/000343875.
5. Tsuchiya N., Sawada Y., Endo I., Saito K., Uemura Y., Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma // World J. Gastroenterol. – 2015. – Vol. 21(37). – P. 10573-10583. https://doi.org/10.3748/wjg.v21.i37.10573.
6. Шайзадина Ф.М., Бейсекова М.М., Кутышева А.Т., Абуова Г.Т., Мендибай С.Т., Кудайбердиева С.М. Эпидемиологическая ситуация вирусных гепатитов в небольшом городе центрального Казахстана // Межд. Ж. Прикл. Фундам. Иссл. [Shajzadina F.M., Bejsekova M.M., Kutysheva A.T., Abuova G.T., Mendibaj S.T., Kudajberdieva S.M. E’pidemiologicheskaya situaciya virusnyx gepatitov v nebol’shom gorode central’nogo Kazaxstana // Mezhd. Zh. Prikl. Fundam. Issl. (in Russ.)]. – 2013. – №8(3) – С. 88-89. https://applied-research.ru/ru/article/view?id=3891.
7. Singal A.G., Pillai A., Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis // PLoS Med. – 2014. – Vol. 11(4). – P. e1001624. https://doi.org/10.1371/journal.pmed.1001624.
8. Reichl P., Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: an update for clinicians (review) // Oncol. Rep. –2016. – Vol. 36(2). – P. 613-625. https://doi.org/10.3892/or.2016.4842.
9. Singal A.G., Mittal S., Yerokun O.A., Ahn C., Marrero J.A., Yopp A.C., Parikh N.D., Scaglione S.J. Hepatocellular carcinoma screening associated with early tumor detection and improved survival among patients with cirrhosis in the US // Am. J. Med. – 2017. – Vol. 130(9). – P. 1099-1106. https://doi.org/10.1016/j.amjmed.2017.01.021.
10. White D.L., Thrift A.P., Kanwal F., Davila J., El-Serag H.B. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012 // Gastroenterology. – 2017. – Vol. 152(4). – P. 812-820. https://doi.org/10.1053/j.gastro.2016.11.020.
11. Marrero J.A., Ahn J., Reddy K.R., American college of gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions // Am J. Gastroenterol. – 2014. – 109(9). – P. 1328-1347. https://doi.org/10.1038/ajg.2014.213.
12. Axley P., Ahmed Z., Ravi S., Singal A.K. Hepatitis C virus and hepatocellular carcinoma: A narrative review // J. Clin. Transl. Hepatol. – 2018. – Vol. 6(1). – P. 79-84. https://doi.org/10.14218/JCTH.2017.00067.
13. Masuzaki R., Yoshida H., Omata M. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C Virus-related chronic hepatitis/liver cirrhosis // Oncology. – 2010. – Vol. 78(1). – P. 17-23. https://doi.org/10.1159/000315225.
14. Nakamura S., Nouso K., Sakaguchi K., Ito Y.M., Ohashi Y., Kobayashi Y., Toshikuni N., Tanaka H., Miyake Y., Matsumoto E., Shiratori Y. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size // Am. J. Gastroenterol. – 2006. – Vol. 101(9). – P. 2038-2043. https://doi.org/10.1111/j.1572-0241.2006.00681.x.
15. Bralic V. Hepatocellular carcinoma – news in diagnosis, follow up and treatment and role of family physician // Acta Med. Croatica. – 2015. – Vol. 69(4). – P. 327-331. https://hrcak.srce.hr/154162.
16. Malek N.P., Schmidt S., Huber P., Manns M.P, Greten T.F. The diagnosis and treatment of hepatocellular carcinoma // Dtsch. Arztebl. Int. – 2014. – Vol. 111(7). – P. 101-106. https://doi.org/10.3238/arztebl.2014.0101.
17. Lai S.W., Chen P.C., Liao K.F., Muo C.H., Lin C.C., Sung F.C. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study // Am. J. Gastroenterol. – 2012. – Vol. 107(1). – P. 46-52. https://doi.org/10.1038/ajg.2011.384.
18. Donadon V., Balbi M., Mas M.D., Casarin P., Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease // Liver Int. – 2010. – Vol. 30(5). – P. 750-758. https://doi.org/10.1111/j.1478-3231.2010.02223.x.
19. El-Serag H.B. Hepatocellular carcinoma // New Engl. J. Med. – 2011. – Vol. 365(12). – P. 1118-1127. https://doi.org/10.1056/NEJMra1001683.
20. Kitamura S., Kai K., Nakamura M., Tanaka T., Ide T., Noshiro H., Sueoka E., Aishima S. Cytological comparison between hepatocellular carcinoma and intrahepatic cholangiocarcinoma by image analysis software using touch smear samples of surgically resected specimens // Cancers (Basel). – 2022. – Vol. 14(9). – P. 2301. https://doi.org/10.3390/cancers14092301.
21. Benson A.B., D’Angelica M.I., Abbott D.E., Anaya D.A., Anders R., Are C., Bachini M., Borad M., Brown D., Burgoyne A., Chahal P., Chang D.T., Cloyd J., Covey A.M., Glazer E.S., Goyal L., Hawkins W.G., Iyer R., Jacob R., Kelley R.K., Kim R., Levine M., Palta M., Park J.O., Raman S., Reddy S., Sahai V., Schefter T., Singh G., Stein S., Vauthey J.N., Venook A.P., Yopp A., McMillian N.R., Hochstetler C., Darlow S.D. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology // J. Natl. Compr. Canc. Netw. – 2021. – Vol. 19(5). – P. 541-565. https://doi.org/10.6004/jnccn.2021.0022.
22. Peng Z.W., Zhang Y.J., Liang H.H., Lin X.J., Guo R.P., Chen M.S. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial // Radiology. – 2012. – Vol. 262(2). – P. 689-700. https://doi.org/10.1148/radiol.11110637.
23. Chang C., Chau G.Y., Lui W.Y., Tsay S.H., King K.L., Wu C.W. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver // Arch. Surg. – 2004. – Vol. 139(3). – P. 320-325. https://doi.org/10.1001/archsurg.139.3.320.
24. Sempokuya T., Wong L.L. Ten-year survival and recurrence of hepatocellular cancer // Hepatoma Res. – 2019. – Vol. 5. – P. 38. https://doi.org/10.20517/2394-5079.2019.013
25. Mulier S., Mulier P., Ni Y., Miao Y., Dupas B., Marchal G., De Wever I., Michel L. Complications of radiofrequency coagulation of liver tumours // Br. J. Surg. – 2002. – Vol. 89. – P. 1206-1222. https://doi.org/10.1046/j.1365-2168.2002.02168.x.